Cardiovascular smart medical company Ruixin Medical announced the completion of 50 million yuan Series A+ round of financing, led by China Growth Capital, with participation from Matrix Partners China and Greenriver Investment.
Cardiovascular smart medical company Ruixin Medical announced the completion of 50 million yuan Series A+ round of financing, led by China Growth Capital, with participation fromMatrix Partners ChinaandGreenriver Investment.
Proceeds from this round of financing will mainly be used to accelerate the clinical application of its core products, strengthen the development of other products on the platform, and the construction of the company’s marketing and service systems.
Ruixin Medical was established in December 2017 and is headquartered in Shenzhen.
At present, the products developed by the company are widely used in the detection of cardiovascular and cerebrovascular diseases. In less than two years, Ruixin has received three rounds of financing totaling over 100 million yuan.
In terms of the team, the three co-founders of Ruixin Medical, Zheng Lingxiao, Lan Hongzhi and Ma Jun, are all doctors from famous American Universities and has worked for many years in the fields of medical imaging and fluid mechanics.
After two years, Ruixin has formed a R&D team with innovation as its core value, accounting for 50% of the company’s staff.In the meantime, Ruixin’s business team comes from top foreign companies who have been deeply involved in the cardiovascular field for more than 10 years and have rich clinical promotion experience.